Valneva to Further Consolidate its Operations in France

Core Insights - Valneva SE is implementing a strategic initiative to optimize its organizational footprint in France to enhance operational effectiveness and ensure long-term success [1] Group 1: Operational Changes - The company plans to consolidate its French operations at the Lyon location, closing the Nantes site which includes operational and certain pre-clinical R&D activities [2] - All R&D activities will be centralized at the company's site in Vienna, streamlining operations and improving efficiency in France [2][8] Group 2: Relocation and Industry Positioning - Valneva will relocate its registered office back to Lyon, a city recognized as a leading vaccine hub, home to major players like Sanofi Pasteur and the Mérieux group [3] - This strategic move positions Valneva to concentrate its operations in an ideal location for vaccine development [3] Group 3: Employee Support - The company is committed to supporting employees during this transition and providing assistance to ensure a smooth process for all impacted team members [4] Group 4: Company Overview - Valneva is a specialty vaccine company focused on developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases [5] - The company has advanced multiple vaccines from early R&D to approvals and currently markets three proprietary travel vaccines [6]